[go: up one dir, main page]

HK1091724A1 - Formulations comprising ecteinascidin and a disaccharide - Google Patents

Formulations comprising ecteinascidin and a disaccharide Download PDF

Info

Publication number
HK1091724A1
HK1091724A1 HK06112191A HK06112191A HK1091724A1 HK 1091724 A1 HK1091724 A1 HK 1091724A1 HK 06112191 A HK06112191 A HK 06112191A HK 06112191 A HK06112191 A HK 06112191A HK 1091724 A1 HK1091724 A1 HK 1091724A1
Authority
HK
Hong Kong
Prior art keywords
solution
formulations
ecteinascidin
formulation
disaccharide
Prior art date
Application number
HK06112191A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1091724B (en
Inventor
Pilar Calvo Salve
Maria Tobio Barreira
Bastiaan Nuijen
Jacob Hendrik Beijnen
Original Assignee
Pharma Mar S.A., Sociedad Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1091724(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar S.A., Sociedad Unipersonal filed Critical Pharma Mar S.A., Sociedad Unipersonal
Publication of HK1091724A1 publication Critical patent/HK1091724A1/en
Publication of HK1091724B publication Critical patent/HK1091724B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06112191.6A 2004-10-29 2006-11-06 Formulations comprising ecteinascidin and a disaccharide HK1091724B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62381304P 2004-10-29 2004-10-29
US623813P 2004-10-29

Publications (2)

Publication Number Publication Date
HK1091724A1 true HK1091724A1 (en) 2007-01-26
HK1091724B HK1091724B (en) 2007-11-23

Family

ID=

Also Published As

Publication number Publication date
IL182776A (en) 2010-06-30
KR20070091121A (ko) 2007-09-07
NO328035B1 (no) 2009-11-10
UA91032C2 (xx) 2010-06-25
PE20060925A1 (es) 2006-10-23
HN2005029978A (es) 2009-10-27
TW200621256A (en) 2006-07-01
MXPA05011650A (es) 2006-05-17
US8895557B2 (en) 2014-11-25
AR051653A1 (es) 2007-01-31
RS50510B (sr) 2010-03-02
JP4268163B2 (ja) 2009-05-27
JP2006124393A (ja) 2006-05-18
PL1658848T3 (pl) 2007-12-31
ATE368461T1 (de) 2007-08-15
NO20072713L (no) 2007-07-19
US20150094313A1 (en) 2015-04-02
SV2006002283A (es) 2006-07-20
CN1823794A (zh) 2006-08-30
DE602005001833T2 (de) 2008-04-17
PT1658848E (pt) 2007-11-05
ES2290844T3 (es) 2008-02-16
KR101188691B1 (ko) 2012-10-09
WO2006046079A1 (en) 2006-05-04
JO2464B1 (en) 2009-01-20
CN102018714A (zh) 2011-04-20
IL182776A0 (en) 2007-08-19
TWI296523B (en) 2008-05-11
BRPI0517238B1 (pt) 2021-11-09
US20060094687A1 (en) 2006-05-04
AU2005227421A1 (en) 2006-05-18
CA2520979C (en) 2009-03-24
CA2520979A1 (en) 2006-02-15
EP1658848B1 (en) 2007-08-01
CY1107773T1 (el) 2013-06-19
GT200500314A (es) 2007-03-22
ZA200703450B (en) 2008-09-25
HRP20070374T3 (en) 2007-10-31
AR110986A2 (es) 2019-05-22
SI1658848T1 (sl) 2007-12-31
CN102018714B (zh) 2014-01-08
PA8650801A1 (es) 2006-09-22
MY139049A (en) 2009-08-28
RU2007119724A (ru) 2008-12-10
NZ554761A (en) 2010-01-29
BRPI0517238A (pt) 2008-10-07
RU2382647C2 (ru) 2010-02-27
DK1658848T3 (da) 2007-11-26
AU2005227421B2 (en) 2007-06-28
EP1658848A1 (en) 2006-05-24
DE602005001833D1 (de) 2007-09-13
UY29183A1 (es) 2006-05-31
US10322183B2 (en) 2019-06-18
PE20100089A1 (es) 2010-03-01

Similar Documents

Publication Publication Date Title
EP1658848B1 (en) Formulations comprising ecteinascidin and a disaccharide
AU2020244613C1 (en) Methods for treatment of diseases
JP6869941B2 (ja) ある含有量のマイトマイシンcを有する凍結乾燥医薬組成物を製造する方法
EP1968592B1 (en) Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds and a disaccharide for treating proliferative diseases
EP2052723A1 (en) Stable lyophilized preparation
WO2009051626A1 (en) Cephalosporin derivative formulation
JP2020125359A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
HK1091724B (en) Formulations comprising ecteinascidin and a disaccharide
CN107837237B (zh) 一种培美曲塞二钠药物组合物及其制备方法
HK1122743B (en) Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds and a disaccharide for treating proliferative diseases